Peringatan Keamanan

The most frequent adverse effects were nausea, vomiting and muscle spasm. Soybean oil-based lipid emulsions can cause hypersensitivity reactions and risks of catheter-related infections. Fat overload syndrome is a rare condition that has been reported with intravenous lipid emulsions, due to a reduced or limited ability to metabolize lipids accompanied by prolonged plasma clearance. Worsensing conditions of the patients can be seen including hematological effects, declined hepatic function and central nervous system manifestations. Hypertriglyceridema may occur. Preterm and small-for-gestational-age infants have poor clearance of intravenous lipid emulsion and increased free fatty acid plasma levels following lipid emulsion infusion, leading to accumulation in lungs. It is advised not to exceed 0.75 mL/kg/hour.

Soybean oil

DB09422

biotech approved

Deskripsi

Derived from soybeans, soybean oil is a common vegetable oil and a source of polyunsaturated and saturated fatty acids. It is a complex mixture of triglycerides where per 100 g, soybean oil has 16 g of saturated fat, 23 g of monounsaturated fat, and 58 g of polyunsaturated fat. The major component fatty acids are linoleic (48% - 58%), oleic (17% - 30%), palmitic (9% -13%), linolenic (4% - 11%), and stearic (2.5% - 5.0%). It is used as a cooking oil and lipid emulsion for parenteral nutrition in clinical settings. Soybean oil-based lipid emulsion is the only FDA-approved lipid formulation for clinical use.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi After triglycerides are hydrolyzed, fatty acids can enter the tissues where they may be oxidized or resynthesized into triglcerides and stored.
Klirens (Clearance) The elimination rate of lipid emulsions depends on particle size, fatty acid composition, apolipoprotein content of the lipid globules, lipoprotein lipase activity, and hepatic lipase activity [L854].

Absorpsi

Following infusion, there is a transient increase in plasma triglycerides.

Metabolisme

The infused lipid particles are removed from the bloodstream in a manner generally thought to be similar to the enzymatic clearance of naturally produced chylomicrons formed after enteral fat intake. The triglycerides are hydrolyzed to free fatty acids and glycerol by the enzyme lipoprotein lipase. In the liver, circulating free fatty acids are oxidized or converted to very low density lipoproteins by hepatic lipase that re-enter the bloodstream.

Rute Eliminasi

Converted carbon dioxide from smaller fatty acid units are excreted by the lungs.

Interaksi Obat

87 Data
Lepirudin The therapeutic efficacy of Lepirudin can be decreased when used in combination with Soybean oil.
Bivalirudin The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Soybean oil.
Alteplase The therapeutic efficacy of Alteplase can be decreased when used in combination with Soybean oil.
Urokinase The therapeutic efficacy of Urokinase can be decreased when used in combination with Soybean oil.
Reteplase The therapeutic efficacy of Reteplase can be decreased when used in combination with Soybean oil.
Anistreplase The therapeutic efficacy of Anistreplase can be decreased when used in combination with Soybean oil.
Tenecteplase The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Soybean oil.
Abciximab The therapeutic efficacy of Abciximab can be decreased when used in combination with Soybean oil.
Drotrecogin alfa The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Soybean oil.
Streptokinase The therapeutic efficacy of Streptokinase can be decreased when used in combination with Soybean oil.
Dicoumarol The therapeutic efficacy of Dicoumarol can be decreased when used in combination with Soybean oil.
Argatroban The therapeutic efficacy of Argatroban can be decreased when used in combination with Soybean oil.
Ardeparin The therapeutic efficacy of Ardeparin can be decreased when used in combination with Soybean oil.
Phenindione The therapeutic efficacy of Phenindione can be decreased when used in combination with Soybean oil.
Fondaparinux The therapeutic efficacy of Fondaparinux can be decreased when used in combination with Soybean oil.
Warfarin The therapeutic efficacy of Warfarin can be decreased when used in combination with Soybean oil.
Pentosan polysulfate The therapeutic efficacy of Pentosan polysulfate can be decreased when used in combination with Soybean oil.
Phenprocoumon The therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Soybean oil.
Edetic acid The therapeutic efficacy of Edetic acid can be decreased when used in combination with Soybean oil.
Dipyridamole The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Soybean oil.
Heparin The therapeutic efficacy of Heparin can be decreased when used in combination with Soybean oil.
Enoxaparin The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Soybean oil.
Epoprostenol The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Soybean oil.
Acenocoumarol The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Soybean oil.
4-hydroxycoumarin The therapeutic efficacy of 4-hydroxycoumarin can be decreased when used in combination with Soybean oil.
Coumarin The therapeutic efficacy of Coumarin can be decreased when used in combination with Soybean oil.
Ximelagatran The therapeutic efficacy of Ximelagatran can be decreased when used in combination with Soybean oil.
Desmoteplase The therapeutic efficacy of Desmoteplase can be decreased when used in combination with Soybean oil.
Defibrotide The therapeutic efficacy of Defibrotide can be decreased when used in combination with Soybean oil.
Ancrod The therapeutic efficacy of Ancrod can be decreased when used in combination with Soybean oil.
Beraprost The therapeutic efficacy of Beraprost can be decreased when used in combination with Soybean oil.
Fibrinolysin The therapeutic efficacy of Fibrinolysin can be decreased when used in combination with Soybean oil.
SR-123781A The therapeutic efficacy of SR-123781A can be decreased when used in combination with Soybean oil.
Prasugrel The therapeutic efficacy of Prasugrel can be decreased when used in combination with Soybean oil.
Rivaroxaban The therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Soybean oil.
Sulodexide The therapeutic efficacy of Sulodexide can be decreased when used in combination with Soybean oil.
Semuloparin The therapeutic efficacy of Semuloparin can be decreased when used in combination with Soybean oil.
Idraparinux The therapeutic efficacy of Idraparinux can be decreased when used in combination with Soybean oil.
Cangrelor The therapeutic efficacy of Cangrelor can be decreased when used in combination with Soybean oil.
Astaxanthin The therapeutic efficacy of Astaxanthin can be decreased when used in combination with Soybean oil.
Apixaban The therapeutic efficacy of Apixaban can be decreased when used in combination with Soybean oil.
Otamixaban The therapeutic efficacy of Otamixaban can be decreased when used in combination with Soybean oil.
Amediplase The therapeutic efficacy of Amediplase can be decreased when used in combination with Soybean oil.
Dabigatran etexilate The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Soybean oil.
Danaparoid The therapeutic efficacy of Danaparoid can be decreased when used in combination with Soybean oil.
Dalteparin The therapeutic efficacy of Dalteparin can be decreased when used in combination with Soybean oil.
Tinzaparin The therapeutic efficacy of Tinzaparin can be decreased when used in combination with Soybean oil.
Ferulic acid The therapeutic efficacy of Ferulic acid can be decreased when used in combination with Soybean oil.
(R)-warfarin The therapeutic efficacy of (R)-warfarin can be decreased when used in combination with Soybean oil.
Ethyl biscoumacetate The therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Soybean oil.
Nadroparin The therapeutic efficacy of Nadroparin can be decreased when used in combination with Soybean oil.
Triflusal The therapeutic efficacy of Triflusal can be decreased when used in combination with Soybean oil.
Ticagrelor The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Soybean oil.
Ditazole The therapeutic efficacy of Ditazole can be decreased when used in combination with Soybean oil.
Vorapaxar The therapeutic efficacy of Vorapaxar can be decreased when used in combination with Soybean oil.
Edoxaban The therapeutic efficacy of Edoxaban can be decreased when used in combination with Soybean oil.
Sodium citrate The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Soybean oil.
Dextran The therapeutic efficacy of Dextran can be decreased when used in combination with Soybean oil.
Bemiparin The therapeutic efficacy of Bemiparin can be decreased when used in combination with Soybean oil.
Reviparin The therapeutic efficacy of Reviparin can be decreased when used in combination with Soybean oil.
Parnaparin The therapeutic efficacy of Parnaparin can be decreased when used in combination with Soybean oil.
Certoparin The therapeutic efficacy of Certoparin can be decreased when used in combination with Soybean oil.
Desirudin The therapeutic efficacy of Desirudin can be decreased when used in combination with Soybean oil.
Antithrombin Alfa The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Soybean oil.
Protocatechualdehyde The therapeutic efficacy of Protocatechualdehyde can be decreased when used in combination with Soybean oil.
Protein C The therapeutic efficacy of Protein C can be decreased when used in combination with Soybean oil.
Antithrombin III human The therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Soybean oil.
Letaxaban The therapeutic efficacy of Letaxaban can be decreased when used in combination with Soybean oil.
Darexaban The therapeutic efficacy of Darexaban can be decreased when used in combination with Soybean oil.
Betrixaban The therapeutic efficacy of Betrixaban can be decreased when used in combination with Soybean oil.
Nafamostat The therapeutic efficacy of Nafamostat can be decreased when used in combination with Soybean oil.
Monteplase The therapeutic efficacy of Monteplase can be decreased when used in combination with Soybean oil.
Gabexate The therapeutic efficacy of Gabexate can be decreased when used in combination with Soybean oil.
Troxerutin The therapeutic efficacy of Troxerutin can be decreased when used in combination with Soybean oil.
Fluindione The therapeutic efficacy of Fluindione can be decreased when used in combination with Soybean oil.
Protein S human The therapeutic efficacy of Protein S human can be decreased when used in combination with Soybean oil.
Brinase The therapeutic efficacy of Brinase can be decreased when used in combination with Soybean oil.
Clorindione The therapeutic efficacy of Clorindione can be decreased when used in combination with Soybean oil.
Diphenadione The therapeutic efficacy of Diphenadione can be decreased when used in combination with Soybean oil.
Tioclomarol The therapeutic efficacy of Tioclomarol can be decreased when used in combination with Soybean oil.
Melagatran The therapeutic efficacy of Melagatran can be decreased when used in combination with Soybean oil.
Saruplase The therapeutic efficacy of Saruplase can be decreased when used in combination with Soybean oil.
(S)-Warfarin The therapeutic efficacy of (S)-Warfarin can be decreased when used in combination with Soybean oil.
Tocopherylquinone The therapeutic efficacy of Tocopherylquinone can be decreased when used in combination with Soybean oil.
Dabigatran The therapeutic efficacy of Dabigatran can be decreased when used in combination with Soybean oil.
Dermatan sulfate The therapeutic efficacy of Dermatan sulfate can be decreased when used in combination with Soybean oil.
Limaprost The therapeutic efficacy of Limaprost can be decreased when used in combination with Soybean oil.

Target Protein

Peroxisome proliferator-activated receptor alpha PPARA

Referensi & Sumber

Artikel (PubMed)
  • PMID: 22488002
    Umpierrez GE, Spiegelman R, Zhao V, Smiley DD, Pinzon I, Griffith DP, Peng L, Morris T, Luo M, Garcia H, Thomas C, Newton CA, Ziegler TR: A double-blind, randomized clinical trial comparing soybean oil-based versus olive oil-based lipid emulsions in adult medical-surgical intensive care unit patients requiring parenteral nutrition. Crit Care Med. 2012 Jun;40(6):1792-8. doi: 10.1097/CCM.0b013e3182474bf9.
  • PMID: 21832112
    Siqueira J, Smiley D, Newton C, Le NA, Gosmanov AR, Spiegelman R, Peng L, Osteen SJ, Jones DP, Quyyumi AA, Ziegler TR, Umpierrez GE: Substitution of standard soybean oil with olive oil-based lipid emulsion in parenteral nutrition: comparison of vascular, metabolic, and inflammatory effects. J Clin Endocrinol Metab. 2011 Oct;96(10):3207-16. doi: 10.1210/jc.2011-0480. Epub 2011 Aug 10.
  • PMID: 20473991
    Jiang ZM, Wilmore DW, Wang XR, Wei JM, Zhang ZT, Gu ZY, Wang S, Han SM, Jiang H, Yu K: Randomized clinical trial of intravenous soybean oil alone versus soybean oil plus fish oil emulsion after gastrointestinal cancer surgery. Br J Surg. 2010 Jun;97(6):804-9. doi: 10.1002/bjs.6999.
  • PMID: 20531018
    Tomsits E, Pataki M, Tolgyesi A, Fekete G, Rischak K, Szollar L: Safety and efficacy of a lipid emulsion containing a mixture of soybean oil, medium-chain triglycerides, olive oil, and fish oil: a randomised, double-blind clinical trial in premature infants requiring parenteral nutrition. J Pediatr Gastroenterol Nutr. 2010 Oct;51(4):514-21. doi: 10.1097/MPG.0b013e3181de210c.
  • PMID: 16651709
    Nishimura M, Yamaguchi M, Naito S, Yamauchi A: Soybean oil fat emulsion to prevent TPN-induced liver damage: possible molecular mechanisms and clinical implications. Biol Pharm Bull. 2006 May;29(5):855-62.
  • PMID: 26630252
    Kapoor V, Glover R, Malviya MN: Alternative lipid emulsions versus pure soy oil based lipid emulsions for parenterally fed preterm infants. Cochrane Database Syst Rev. 2015 Dec 2;(12):CD009172. doi: 10.1002/14651858.CD009172.pub2.

Contoh Produk & Brand

Produk: 55 • International brands: 0
Produk
  • 10% Travamulsion Liq IV
    Liquid • - • Intravenous • Canada • Approved
  • 20% Travamulsion Liq IV
    Liquid • - • Intravenous • Canada • Approved
  • Cipherkey Hair Tonic
    Liquid • 8 g/100mL • Topical • US • OTC
  • CIPHERKEYshampoo
    Shampoo • 3 g/100mL • Topical • US • OTC
  • Clinoleic 20%
    Emulsion • - • Intravenous • Canada • Approved
  • Clinolipid
    Injection, emulsion • - • Intravenous • US • Approved
  • Colip 20%
    Emulsion • - • Intravenous • Canada • Approved
  • essenHERB Soybean 90 Deep Cleansing
    Oil • 91.6 g/100mL • Topical • US • OTC
Menampilkan 8 dari 55 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul